{"id":"W4402415074","doi":"10.1183/13993003.01551-2024","title":"Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study","year":2024,"lang":"en","type":"article","venue":"European Respiratory Journal","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Medical Research Council; University of North Carolina at Chapel Hill; Grifols; Imam Abdulrahman Bin Faisal University; Sanofi Genzyme; Deutsches Zentrum für Lungenforschung; Galderma; School of Medicine, New York University; Meiji Seika Pharma; Pfizer; York University; Incyte; Sun Pharma; Dermira; Vertex Pharmaceuticals; MannKind Corporation; Regeneron Pharmaceuticals; Genentech; University of Dundee; LEO Pharma; Gilead Sciences; Ortho Dermatologics; Eli Lilly and Company; AstraZeneca; Chiesi Farmaceutici; CSL Behring; Bundesministerium für Bildung und Forschung; INOVIO Pharmaceuticals; Insmed; Medical Research Council; Teva Pharmaceutical Industries; Sanofi; Deutsche Forschungsgemeinschaft; GlaxoSmithKline; Boehringer Ingelheim; Amgen","keywords":"Medicine; Placebo; Exacerbation; Bronchiectasis; Internal medicine; Gastroenterology; Dipeptidyl peptidase-4; Pharmacology; Lung; Endocrinology; Pathology; Diabetes mellitus","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003382733,0.001741624,0.004509966,0.000433616,0.000308868,0.0009692443,0.0009885206,0.00236361,0.006078084],"category_scores_gemma":[0.002146856,0.0007980285,0.002205038,0.0003912751,0.0008943464,0.0009402941,0.000474372,0.002038993,0.0009521522],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004482887,"about_ca_system_score_gemma":0.0009988111,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005009166,"about_ca_topic_score_gemma":0.001255494,"domain_scores_codex":[0.9988769,0.0006252764,0.0001009189,0.0001787445,0.0001069256,0.0001111659],"domain_scores_gemma":[0.9988285,0.0003742557,0.0003033726,0.00008296251,0.0001173581,0.000293479],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9625834,0.009067702,0.0004627205,0.001974853,0.001117178,0.00005930325,0.00007157876,0.0002345986,0.008225083,0.00007274577,0.0006332668,0.01549753],"study_design_scores_gemma":[0.8878775,0.1091421,0.001484146,0.00004404795,0.0004693678,0.00003382418,0.00001422172,0.0001847868,0.0002702585,0.00004831759,0.0004207916,0.00001066831],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9738131,0.0117857,0.00119018,0.0006847263,0.0004584745,0.008705098,0.001551175,0.0002192392,0.001592415],"genre_scores_gemma":[0.9702468,0.0073168,0.00415835,0.001754193,0.0006253922,0.01053659,0.00158399,0.00004128337,0.003736757],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006078084,"threshold_uncertainty_score":0.02033323,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03791802320327579,"score_gpt":0.3416617243337132,"score_spread":0.3037437011304374,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}